A Phase 4 interventional study of Acetaminophen group and Sufentanil group in Postoperative Delirium, sponsored by Xiangya Hospital of Central South University. Recruiting at 1 site in China. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Xiangya Hospital of Central South University · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 185 studies in Emergence Delirium with a site in China — 64 open to participants now, 65 under way, 1 of them phase 3. Emergence Delirium · China.
Among the 185 studies in Emergence Delirium with a site in China, this one is the 10th largest by planned enrollment of the 111 interventional ones that give a count, is one of 25 that started in 2026, is one of 31 in phase 4, reaches primary completion later than 41 of the 64 other live ones, and was the 147th registered.
753 studies on the registry are indexed under Emergence Delirium; 261 are open to participants now.
Browse Emergence Delirium studies →64 of the 185 studies in Emergence Delirium with a site in China are open now. Recruiting first, the newest first:
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 65–85
Nanjing First Hospital, Nanjing Medical University · Sites in China
Ages 65–90 · Healthy volunteers
Peking University First Hospital · Sites in China
Ages 65+ · Healthy volunteers
Peking University People's Hospital · Sites in China
Ages 65+ · Healthy volunteers
Fujian Medical University Union Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 141 Emergence Delirium studies recruiting now, 78 (55%) set no upper age limit and 43 (30%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
185 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 25 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,092 is above the median of 120 across 467 interventional studies indexed under Emergence Delirium.
Median enrollment 225 across the 111 interventional studies, 300 across the 74 observational. Of the 74 that completed or were terminated, 2 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 185 have an industry lead sponsor. The 10 most frequent:
Xiangya Hospital of Central South University is the lead sponsor of 177 studies on the registry; 80 are open to participants now.
Xiangya Hospital of Central South University has 1 study filed under Emergence Delirium — fewer than ten, so there is no comparison to draw.
21 of the studies in Emergence Delirium with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06361238Phase 3The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolLiraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery | 2027-03-31 |
| NCT07880938The First Hospital of Jilin UniversityIntranasal Dexmedetomidine Combined With Esketamine for Emergence Quality After Suspension Laryngoscopy | 2026-12 |
| NCT07523334Peking University First HospitalImpact of Esketamine on Delayed Neurocognitive Recovery in Older Patients | 2026-12 |
| NCT07351474The First Affiliated Hospital with Nanjing Medical UniversityRemimazolam for Reducing Postoperative Delirium in Elderly Patients Undergoing Laparoscopic Gastrectomy | 2026-12-25 |
| NCT07394647The First Affiliated Hospital of Zhejiang Chinese Medical UniversityTranscutaneous Auricular Vagus Nerve Stimulation for Prevention of Emergence Agitation and Delirium in Children Undergoing Tonsillectomy and Adenoidectomy | 2026-12-30 |
Add all 21 to your calendar (.ics) → With an account.
Among the 185 studies in Emergence Delirium with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this multicenter randomized controlled study is to evaluate the effect of an intravenous acetaminophen-mannitol opioid-sparing analgesic strategy on the cumulative incidence of POD, compared with an intravenous sufentanil-based opioid analgesic strategy.
Delirium is a common complication after surgery. It is associated with increased morbidity and mortality, longer intensive care unit (ICU) and hospital stay, prolonged mechanical ventilation, higher risk of institutionalization, and higher healthcare cost. Depending on patient population and screening method, the incidence of delirium in elderly patients admitted to ICU can be as high as 58-76%. The choice of analgesics and the adequacy of pain control are among the modifiable precipitating factors for postoperative delirium (POD). Whether the use of intravenous acetaminophen decreases the occurrence of POD in older noncardiac surgical patients admitted to ICU remains inadequately studied.
Objectives: To evaluate the effect of an intravenous acetaminophen-mannitol opioid-sparing analgesic strategy on the cumulative incidence of POD, compared with an intravenous sufentanil-based opioid analgesic strategy, in older noncardiac surgical patients admitted to ICU.
Study design: A randomized controlled trial. Setting: 34 ICUs from different regions across China. Patients: 1092 older patients (≥ 60 years), having noncardiac surgery and admitted to ICU after surgery, are eligible.
Intervention: Patients are randomly assigned to intravenous acetaminophen or sufentanil groups. Intravenous acetaminophen is the analgesic of choice for patients in the acetaminophen group. Intravenous sufentanil is the analgesic of choice for patients in the sufentanil group (control).
Outcomes: The primary endpoint is the incidence of delirium within the first 5 days after surgery. Delirium is assessed using the confusion assessment method for the intensive care unit (CAM-ICU).The secondary outcomes include the duration of delirium occurring within postoperative days 1-5 ;analgesic effect within postoperative days 1-5; cumulative opioid exposure during the 48-hour intervention will be reported as drug-specific cumulative doses, including scheduled sufentanil and all rescue opioids; sleep quality within postoperative days 1-5; length of postoperative ICU stay and hospital stay; incidence of non delirium complications within 30 days after surgery; in hospital and 30 day postoperative all cause mortality, and quality of life and cognitive function in 30 day postoperative survivors. Exploratory outcomes include delirium related biomarkers and neurological function tests measured on postoperative day 1.Safety outcomes include the Hepatic adverse events ,adverse event and Serious adverse event .
Predicted duration of the study: 24 months.
The criteria were revised on the registry on Oct 29, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients who meet any of the following criteria will be excluded.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intravenous acetaminophen is the analgesic of choice for patients in the acetaminophen group
Drug: Acetaminophen group
Intravenous sufentanil is the analgesic of choice for patients in the sufentanil group
Drug: Sufentanil group
The pain in this group is controlled using acetaminophen-mannitol (Paracetamol and Maninitol Injection, Yichang Renfu Medicine Co., Ltd., China), 500 mg, intravenous bolus, every 6 hours for the first 48 hours after randomization. The severity of pain is assessed using NRS/CPOT every 15 minutes during the first hour after randomization with study drug infusion and then once every 12 hours needed.The NRS will be used for awake patients, and the CPOT will be used for mechanically ventilated patients.
The pain in this group is controlled using sufentanil (Yichang Renfu Medicine Co., Ltd., China) intravenous infusion with a rate of 0.05 μg/kg/h. The severity of pain is assessed using NRS/CPOT every 15 minutes during the first hour after randomization with study drug infusion and then once every 12 hours needed.The NRS will be used for awake patients, and the CPOT will be used for mechanically ventilated patients.
Incidence of delirium
Delirium assessed using CAM-ICU every 12 hours (8am, 8 pm) during postoperative days 1-5 and RASS transform at any time
Time frame: postoperative 1- 5 days
Duration of delirium
Duration of delirium, defined as the number of postoperative days/hours during which delirium is present.Delirium assessed using CAM-ICU every 12 hours (8am, 8 pm) during postoperative days 1-5 and RASS transform at any time.
Time frame: postoperative 1- 5 days
Severity of pain
Severity of pain assessed using numeric rating scale (NRS)/the Critical-Care Pain Observation Tool (CPOT) , 8am and 8pm, twice a day, for 5 day.The NRS will be used for awake patients, and the CPOT will be used for mechanically ventilated patients.The NRS scale consists of 11 points from 0 to 10, where 0 indicates "no pain" and 10 indicates "severe pain". Patients select the corresponding number based on their pain level. \<4 points indicate mild pain (no impact on sleep), 4-6 points indicate moderate pain, and ≥7 points indicate severe pain (pain prevents sleep or causes waking).The CPOT (Critical-Care Pain Observation Tool): Total score range 0-8, where 0 indicates no pain and 8 indicates the worst pain.
Time frame: postoperative days 1-5
opioid exposure
Cumulative opioid exposure during the 48-hour intervention will be reported as drug-specific cumulative doses, including scheduled sufentanil and all rescue opioids.
Time frame: 48-hour after drug infusion
Sleep quality
Subjective quality of sleep assessed using NRS (an 11-point scale where 0 = the best sleep and 10 = the worst sleep) once daily (8:00-10:00 am) during postoperative days 1-5
Time frame: postoperative days 1-5
All-cause mortality
30-days outcome (survival or death) after surgery; Patients will be assessed via phone call if they are discharged before day 30 after surgery
Time frame: 30-day after surgery
Length of ICU stay
Postoperative length of ICU stay, defined as the number of days (or hours) from ICU admission to ICU discharge.
Time frame: From postoperative ICU admission until ICU discharge, assessed for up to 12 months.
Length of hospital stay
Postoperative length of hospital stay, defined as the number of days/hours from surgery to hospital discharge.
Time frame: From the day of surgery until hospital discharge, assessed for up to 12 months.
Incidence of non-delirium-related complications
Complications unrelated to delirium occurring within 30 days postoperatively (e.g., cardiovascular events, cerebrovascular events, renal impairment, GI complications, infections, etc.) are defined as any newly developed complications that may affect patient recovery and require therapeutic intervention (including hospital admission).
Time frame: 30 days after surgery
Quality of life of 30-day survivors
Patients will be assessed with World Health Organization Quality of Life Assessment Instrument Short Form (WHOQOL-BREF) via phone call if they are discharged before day 30 after surgery The scale contains 26 items covering four domains: physiological, psychological, social relations, and environmental. It uses a 1-5-point Likert scale for scoring, and the original scores are converted into a standard score of 0-100. The higher the score, the better the quality of life.
Time frame: day 30 after surgery
Cognitive function of 30-day survivors
Patients will be assessed with TICS-m via phone call if they are discharged before day 30 after surgery
Time frame: day 30 after surgery
Biomarker of delirium
Biomarker of delirium including S100b and NSE on postoperative day 1
Time frame: Postoperative day 1
Neuro monitoring of delirium
Monitoring of neurophysiological function, with detecting SctO2 during postoperative day 1
Time frame: Postoperative day 1
Safety outcomes
Safety outcomes will include hepatic safety events, adverse events (AEs), study drug-related AEs, and serious adverse events (SAEs). Each category will be reported separately as the number and percentage of participants experiencing event, together with the timing of event onset.
Time frame: postoperative days 1-5
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Jan 2027, 11 months after the start.
Of 50 non-industry phase 4 interventional studies under Emergence Delirium, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 33. This study's planned 11 months is below that.
Counting every sponsor, half of 50 studies reached it within 19 months; a quarter within 11 and three quarters within 33.
Start moved once since we started tracking on Sep 25, 2026: Dec 2025 → Feb 2026, on Oct 29, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acetaminophen
Xiangya Hospital of Central South University →